Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR877901ApriorityCriticalpatent/FR1700M/en
Application grantedgrantedCritical
Publication of FR1700MpublicationCriticalpatent/FR1700M/en
C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D309/30—Oxygen atoms, e.g. delta-lactones
Landscapes
Chemical & Material Sciences
(AREA)
Organic Chemistry
(AREA)
FR877901A1961-11-031961-11-03
New drug in particular for the treatment of manifestations due to hyperlipemia or hypercholesterolemia.
ActiveFR1700M
(en)